Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orthofix awarded $150 mil. in damages from Biomet in jury decision on external fixation devices.

This article was originally published in The Gray Sheet

Executive Summary

BIOMET TO APPEAL JURY'S $150 MIL. AWARD TO ORTHOFIX, the Warsaw, Indiana-based company says. In a verdict announced June 2, a jury in the U.S. District Court in Camden, New Jersey, awarded approximately $50 mil. in compensatory damages and $100 mil. in punitive damages to three of Orthofix International's subsidiaries after finding that Biomet's EBI Medical Systems subsidiary breached a 1990 distribution agreement between the firms.

You may also be interested in...



Orthofix v. Biomet

Punitive damages related to breach of contract case filed by Orthofix in 1995 are reduced from $50 mil. to $1 mil. by the U.S. Court of Appeals for the Third Circuit, Biomet reports. However, the court upholds the original compensatory damages of $49 mil. related to the breach of contract suit found in favor of Orthofix in 1997 (1"The Gray Sheet" June 9, 1997, I&W-5). As a result, Biomet will record a $49.9 mil. charge plus interest against pre-tax earnings for the quarter ended May 31. Biomet also says that it is still "considering further legal challenges" in the case

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel